Clinical trial · Observational
The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy
The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- classical Hodgkin lymphoma
- description
- All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
- interventionNames
- Procedure: FDG-PET
Primary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- within 1 month after end of treatment
- measure
- Overall survival
- timeFrame
- within 1 month after end of treatment
- measure
- Disease-free survival
- timeFrame
- within 1 month after end of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed classical Hodgkin lymphoma according to the current World Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted). 2. Clinical stage I-IV. 3. No previous chemotherapy, radiotherapy or other investigational drug for HL. Exclusion Criteria: 1\. None.
References
Publications (0)
Data not yet available